Episode 118: The Journey of a Healthcare Startup CEO With Jennifer Fried

The Journey of a Healthcare Startup CEO With Jennifer Fried

Episode 118: The Journey of a Healthcare Startup CEO With Jennifer Fried

Jennifer Fried, MBA, most recently the CEO of ExplORer Surgical, joins the show to share her story as a co-founder of a successful startup health technology company. She begins by telling her inspiration to start the company with her partner, when and how operating room workflow and efficiency was discovered as an area of unmet need, the steps she took to create the software platform solution and how it functions, struggles she faced when facing potential investors, how the pandemic propelled the platform from a “nice to have” to a “must have,” why the business was eventually sold, and what the lessons learned were from the whole experience.

Related Resources

N/A

Subscribe to Healthcare Unfiltered

Other Episodes You May Enjoy...

Episode 223: From Lab to Statup: Dr. Simrit Parmar on Launching Cellenkos

Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous

Read More

Episode 222: Language Matters: A Patient Perspective

Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those

Read More

Episode 221: Major Progress in Adjuvant Renal Cell Carcinoma

Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease

Read More